Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever

PLoS Neglected Tropical Diseases

Volumn 5, Issue 10, 2011, Pages

  Mendenhall, Michelle ^a   Russell, Andrew ^a   Smee, Donald F ^a   Hall, Jeffery O ^a   Skirpstunas, Ramona ^a,b   Furuta, Yousuke ^c   Gowen, Brian B ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b State of Utah ^*  (United States)

^c TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; FAVIPIRAVIR; PLACEBO; 6-FLUORO-3-HYDROXY-2-PYRAZINECARBOXAMIDE; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARENAVIRUS INFECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; GUINEA PIG; LD 50; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PICHINDE ARENAVIRUS; THROMBOCYTOPENIA; VIRUS HEMORRHAGIC FEVER; VIRUS STRAIN; WEIGHT REDUCTION; AMERICAN HEMORRHAGIC FEVER; ANIMAL; ARENAVIRUS; DISEASE MODEL; DNA SEQUENCE; DRUG EFFECT; GENETICS; HUMAN; MOLECULAR GENETICS; PATHOGENICITY; SURVIVAL; TREATMENT OUTCOME; VIROLOGY;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; ARENAVIRUS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HEMORRHAGIC FEVER, AMERICAN; HUMANS; LETHAL DOSE 50; MALE; MOLECULAR SEQUENCE DATA; PYRAZINES; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80055080528     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001342     Document Type: Article

References (53)

1. Charrel RN, de Lamballerie X, (2003) Arenaviruses other than Lassa virus. Antiviral Research 57: 89-100.
2. Delgado S, Erickson BR, Agudo R, Blair PJ, Vallejo E, et al. (2008) Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 4: e1000047.
3. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, et al. (2009) Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 5: e1000455.
4. Fichet-Calvet E, Rogers DJ, (2009) Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis 3: e388.
5. Enria DA, Briggiler AM, Sanchez Z, (2008) Treatment of Argentine hemorrhagic fever. Antiviral Res 78: 132-139.
6. Maiztegui JI, Fernandez NJ, de Damilano AJ, (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2: 1216-1217.
7. Enria DA, Briggiler AM, Levis S, Vallejos D, Maiztegui JI, et al. (1987) Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. Antiviral Res 7: 353-359.
8. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, et al. (1997) Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clinical Infectious Diseases 24: 718-722.
9. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. Effective therapy with ribavirin. New England Journal of Medicine 314: 20-26.
10. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002) Hemorrhagic fever viruses as biological weapons: medical and public health management. Jama 287: 2391-2405.
11. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, et al. (1997) Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26: 473-477.
12. Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, et al. (1999) Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 4: 211-219.
13. Fisher-Hoch SP, Gborie S, Parker L, Huggins J, (1992) Unexpected adverse reactions during a clinical trial in rural west Africa. Antiviral Res 19: 139-147.
14. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G, (2006) Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 13: 3351-3357.
15. Kochhar DM, Penner JD, Knudsen TB, (1980) Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 52: 99-112.
16. Ferm VH, Willhite C, Kilham L, (1978) Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 17: 93-101.
17. Bausch DG, Hadi CM, Khan SH, Lertora JJ, (2010) Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 51: 1435-1441.
18. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, et al. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46: 977-981.
19. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. (2007) In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51: 3168-3176.
20. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, et al. (2008) Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral research 80: 377-379.
21. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y, (2009) Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53: 202-209.
22. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, et al. (2010) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 107: 882-887.
23. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, et al. (2010) In Vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54: 2517-2524.
24. Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, et al. (2008) Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 3: e3725.
25. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, et al. (2010) T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture. Antimicrob Agents Chemother: In press.
26. Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, et al. (2010) T cell-dependence of Lassa fever pathogenesis. PLoS Pathog 6: e1000836.
27. Kolokoltsova OA, Yun NE, Poussard AL, Smith JK, Smith JN, et al. (2010) Mice lacking interferon {alpha}/{beta} and {gamma} receptors are susceptible to Junin virus infection. J Virol.
28. Jahrling PB, Smith S, Hesse RA, Rhoderick JB, (1982) Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun 37: 771-778.
29. Oubina JR, Carballal G, Videla CM, Cossio PM, (1984) The guinea pig model for Argentine hemorrhagic fever. Am J Trop Med Hyg 33: 1251-1257.
30. Yun NE, Linde NS, Dziuba N, Zacks MA, Smith JN, et al. (2008) Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs. Am J Trop Med Hyg 79: 275-282.
31. Hall WC, Geisbert TW, Huggins JW, Jahrling PB, (1996) Experimental infection of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease. Am J Trop Med Hyg 55: 81-88.
32. Jahrling PB, Hesse RA, Rhoderick JB, Elwell MA, Moe JB, (1981) Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs. Infection and Immunity 32: 872-880.
33. Aronson JF, Herzog NK, Jerrells TR, (1994) Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains. American Journal of Pathology 145: 228-235.
34. Enria DA, Maiztegui JI, (1994) Antiviral treatment of Argentine hemorrhagic fever. Antiviral Research 23: 23-31.
35. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. American Journal of Hygiene 27: 493-497.
36. Zhang L, Marriott K, Aronson JF, (1999) Sequence analysis of the small RNA segment of guinea pig-passaged Pichinde virus variants. Am J Trop Med Hyg 61: 220-225.
37. Zhang L, Marriott KA, Harnish DG, Aronson JF, (2001) Reassortant analysis of guinea pig virulence of pichinde virus variants. Virology 290: 30-38.
38. Scott EP, Aronson JF, (2008) Cytokine patterns in a comparative model of arenavirus haemorrhagic fever in guinea pigs. J Gen Virol 89: 2569-2579.
39. Lan S, McLay Schelde L, Wang J, Kumar N, Ly H, et al. (2009) Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J Virol 83: 6357-6362.
40. Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, et al. (2010) Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia 14: 28-32.
41. Choudhury A, Chung I, Blann AD, Lip GY, (2007) Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol 49: 1957-1964.
42. Geisbert TW, Jahrling PB, (2004) Exotic emerging viral diseases: progress and challenges. Nat Med 10: S110-121.
43. Kunz S, (2009) The role of the vascular endothelium in arenavirus haemorrhagic fevers. Thromb Haemost 102: 1024-1029.
44. Connolly BM, Jenson AB, Peters CJ, Geyer SJ, Barth JF, et al. (1993) Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an immunocytochemical, virologic, and clinical chemistry study. American Journal of Tropical Medicine and Hygiene 49: 10-24.
45. Walker DH, McCormick JB, Johnson KM, Webb PA, Komba-Kono G, et al. (1982) Pathologic and virologic study of fatal Lassa fever in man. American Journal of Pathology 107: 349-356.
46. Gowen BB, Wong MH, Jung KH, Smee DF, Morrey JD, et al. (2010) Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 86: 121-127.
47. Gowen BB, Holbrook MR, (2008) Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res 78: 79-90.
48. Lucia HL, Coppenhaver DH, Baron S, (1989) Arenavirus infection in the guinea pig model: antiviral therapy with recombinant interferon-alpha, the immunomodulator CL246,738 and ribavirin. Antiviral Research 12: 279-292.
49. Soares MM, King SW, Thorpe PE, (2008) Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14: 1357-1362.
50. Gowen BB, Julander JG, London NR, Wong MH, Larson D, et al. (2010) Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol J 7: 240.
51. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, et al. (1987) Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155: 456-464.
52. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
53. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, et al. (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49: 981-986.